Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Lucía Gandullo-Sánchez"'
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-26 (2022)
Abstract The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implicate that targeting HER3 may have
Externí odkaz:
https://doaj.org/article/ab1e967dfa2146b59981aefb16f60db2
Autor:
Sara García-Alonso, Inés Romero-Pérez, Lucía Gandullo-Sánchez, Luis Chinchilla, Alberto Ocaña, Juan Carlos Montero, Atanasio Pandiella
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Abstract Background Treatment of renal cancer has significantly improved with the arrival to the clinic of kinase inhibitors and immunotherapies. However, the disease is still incurable in advanced stages. The fact that several approved inhibitors fo
Externí odkaz:
https://doaj.org/article/2c40237c38a3492d9ab9d62910bcea6b
Autor:
Haidée Aranda-Tavío, Carlota Recio, Pedro Martín-Acosta, Miguel Guerra-Rodríguez, Yeray Brito-Casillas, Rosa Blanco, Vanessa Junco, Javier León, Juan Carlos Montero, Lucía Gandullo-Sánchez, Grant McNaughton-Smith, Juan Manuel Zapata, Atanasio Pandiella, Angel Amesty, Ana Estévez-Braun, Leandro Fernández-Pérez, Borja Guerra
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112330- (2021)
Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently target BCR-ABL1 activ
Externí odkaz:
https://doaj.org/article/92342ec5291144c1b598681c8beb4683
Autor:
María del Mar Noblejas-López, Lucía Gandullo-Sánchez, Eva M. Galán-Moya, Raquel López-Rosa, David Tébar-García, Cristina Nieto-Jiménez, Mónica Gómez-Juárez, Miguel Burgos, Atanasio Pandiella, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5476 (2022)
Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9. Br
Externí odkaz:
https://doaj.org/article/7a179b3875cc48c09e6d42df7b04d5eb
Autor:
Lucía Gandullo‐Sánchez, Emily Capone, Alberto Ocaña, Stefano Iacobelli, Gianluca Sala, Atanasio Pandiella
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 5, Pp n/a-n/a (2020)
Abstract Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. Therefore, it is important to develop novel strategies to
Externí odkaz:
https://doaj.org/article/60c8022f129d4e80a557c5a7b13dcc4b
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Effect of doxorubicin and Cdk4/6i on cells expressing different levels of HER2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8318d5a3d9756e26e2f4f168b7743465
https://doi.org/10.1158/0008-5472.22432560
https://doi.org/10.1158/0008-5472.22432560
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0cd93ffd70867fcd1f27692db14b949
https://doi.org/10.1158/0008-5472.c.6514164
https://doi.org/10.1158/0008-5472.c.6514164
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a498c31e3cd4f923e7ee74e3c1fdda92
https://doi.org/10.1158/0008-5472.22432542.v1
https://doi.org/10.1158/0008-5472.22432542.v1
Autor:
Joaquín Arribas, Cristina Saura, Javier Cortés, Wim H.A. Dokter, Fred A. Dijcks, Verónica Rodilla, Anna Esteve-Codina, Atanasio Pandiella, Lucía Gandullo-Sánchez, Santiago Escrivá-de-Romaní, Sandra Pérez-Ramos, Marta Escorihuela, Beatriz Morancho, Cristina Bernadó Morales, Enrique Javier Arenas, Marta Lalinde-Gutiérrez, Mercedes Nadal-Serrano, Santiago Duro-Sánchez
Extended Materials and Methods and Supplementary figures with legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab2ec453691e74e2206125dfa522618
https://doi.org/10.1158/0008-5472.22432545
https://doi.org/10.1158/0008-5472.22432545
Autor:
Lucía Gandullo-Sánchez, Inés Romero-Pérez, Sara García-Alonso, Juan Carlos Montero, Alberto Ocaña, Atanasio Pandiella, Luis Chinchilla
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Experimental & Clinical Cancer Research : CR
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Experimental & Clinical Cancer Research : CR
© The Author(s).
[Background]: Treatment of renal cancer has significantly improved with the arrival to the clinic of kinase inhibitors and immunotherapies. However, the disease is still incurable in advanced stages. The fact that several appro
[Background]: Treatment of renal cancer has significantly improved with the arrival to the clinic of kinase inhibitors and immunotherapies. However, the disease is still incurable in advanced stages. The fact that several appro